President Donald J. Trump has announced a new agreement with pharmaceutical company AstraZeneca aimed at aligning American drug prices with those paid by other developed countries, known as the most-favored-nation (MFN) price. This marks the second such deal reached under his administration.
The White House states that this initiative is expected to lower costs for both patients and the broader healthcare system in the United States.
AstraZeneca has also committed to investing $50 billion in U.S.-based manufacturing and research and development by 2030 as part of this agreement.
President Trump said these actions are intended to address what he describes as an imbalance, where pharmaceutical companies charge Americans higher prices than those offered to other wealthy nations. "President Trump is taking decisive action to rebalance a system that allows pharmaceutical manufacturers to offer low prices to other wealthy nations while charging Americans significantly higher prices," according to the announcement.
He also emphasized his commitment to prioritizing American patients, stating: "President Trump is delivering on promises for American patients that the political establishment did not believe were possible."
The agreement reflects ongoing efforts by the administration to reduce prescription drug costs and secure domestic supply chains within the pharmaceutical industry.
